International Society of Pharmacovigilance

Committed to safer use of medicines worldwide

ISoP General Assembly | 24 September 2026

InterContinental Hotel Costa Rica at Multiplaza Mall ("Real 1 & 2")
Autop. Próspero Fernández, San José, Escazú, Costa Rica
Scheduled meeting time: 11:30–13:00 (UTC−6) | 17:30–19:00 (UTC)

Present: Omar Aimer (ISoP President), Francesco Salvo (ISoP Vice-President), Felipe Villalobos (ISoP Secretary General), and Comfort Ogar (ISoP Treasurer, attending remotely).

Advisory Board members: Salvatore Crisafulli, Tarek Hammad, Katarina Ilic, Hadir Rostom (remote), Maribel Salas.

Apologies: Brian Edwards.

In Attendance: Sophie Spence and Antoinette Ivins (ISoP Secretariat)

Approximately 250 members of the Society in person and 43 Society members connected online.

Chairs: Omar Aimer (ISoP President) and Felipe Villalobos (ISoP Secretary General)

Agenda

1. Welcome, introductions, housekeeping
2. Approval of Agenda
3. Approval of Minutes of the 2025 General Assembly
4. Overview of the strategic plan 2025–2028 (Introduction by the ISoP President)
   - 4.1 Goal 1 – Position ISoP as the trusted global pharmacovigilance organization through scientific leadership and education.
     - 4.1.1 Scientific Leadership Update
     - 4.1.2 SIG Update
   - 4.2 Goal 2 – Enhance the membership journey by improving benefits, onboarding, and operational support using digital tools.
     - 4.2.1 Member-Centric Plan
     - 4.2.2 Membership and Chapter Report
     - 4.2.3 Communities and Mentorship Report
     - 4.2.4 Student Coordination Report
   - 4.3 Goal 3 – Ensure long-term sustainability by balancing asset stability, expanding funding sources, and supporting priority initiatives.
     - 4.3.1 Communications Report
     - 4.3.2 Global Outreach and Strategic Partnerships
   - 4.4 Goal 4 – Ensure long-term sustainability by balancing asset stability, expanding funding sources, and supporting priority initiatives.
     - 4.4.1 Treasurer's Financial Report
5. Fellowship and Honorary Awards 2026
6. Looking Ahead (ISoP events)
7. Q&A
8. Remarks from ISoP President

1. **Welcome, introductions, housekeeping**

   ISoP Secretary General Felipe Villalobos opened the General Assembly by warmly welcoming members from around the world. Held as a hybrid event and streamed live from Costa Rica during the 25th ISoP Global Meeting, the session was accessible online to all ISoP members.

2. **Approval of Agenda**

   Felipe Villalobos requested approval of the agenda, which was accepted by the General Assembly without amendments.

3. **Approval of Minutes of the 2025 General Assembly**

   Felipe Villalobos presented the 2025 General Assembly minutes for approval. The General Assembly unanimously approved the minutes, with no abstentions or objections recorded. The minutes are available on the ISoP website: https://isoponline.org/about-isop/general-assembly-reports/.

4. **Overview of the strategic plan 2025–2028**

   ISoP President Omar Aimer presented an overview of the ISoP Strategic Plan 2025–2028, explaining how the Society's current activities are aligned with its overall vision and strategic direction. He emphasised the importance of ensuring that the Strategic Plan is understood across the Society and noted that it had been presented and discussed with leaders of Chapters, Communities and Special Interest Groups (SIGs) through four dedicated sessions.

   Omar Aimer reintroduced the ISoP Advisory Board (AB) for 2025–2028, comprising the Executive Committee (EC) and Advisory Board (AB) coordinators responsible for key areas including communications and students, communities and mentorship, strategy and innovation, SIGs, membership and academic activities.

   The ISoP organisational framework was presented, illustrating how the EC and AB work alongside the Scientific Board (SB) and the Society's Chapters, SIGs and Communities. Chapters bring members together geographically, while SIGs connect members according to areas of scientific and professional interest. Communities provide additional opportunities for engagement according to members' professional backgrounds and sectors, including Students, Industry, and Fellows and Honorary Members. Members were encouraged to visit the ISoP website https://isoponline.org/ for further information and opportunities to become involved.

   Omar Aimer highlighted science as a fundamental pillar of trust and ISoP's guiding compass, with the ambition of advancing safety science and strengthening ISoP's position within pharmacovigilance globally.

The four goals of the 2025–2028 Strategic Plan were presented:

1. Position ISoP as the trusted global pharmacovigilance organization through scientific leadership and education – A further priority is expanding access to high-quality pharmacovigilance education through courses, webinars and Chapter and SIG initiatives with a strong focus on global reach and capacity building.

2. Enhance the membership journey by improving benefits, onboarding, and operational support using digital tools –The objective is to strengthen member value, engagement and operational efficiency through improved automation and clear communication, supporting the Society's move towards a more member-centric approach.

3. Ensure long-term sustainability by balancing asset stability, expanding funding sources, and supporting priority initiatives – Strengthen ISoP's reputation as ***the*** global pharmacovigilance organisation while improving communication and engagement with members. This includes strengthening both external visibility and internal communication to increase member awareness, engagement and participation in Society activities.

4. Strengthen ISoP's reputation as the global pharmacovigilance organization while enhancing engaging communication with members – Ensure ISoP's long-term sustainability through asset stability, diversification of funding sources and support for priority strategic initiatives. Omar Aimer noted the importance of maintaining a sustainable financial model to enable the Society to deliver its strategic objectives over the longer term.

Omar Aimer emphasised that ISoP is a non-profit, membership-based Society, with membership fees contributing to its activities and development.

4.1 Goal 1 – Position ISoP as the trusted global pharmacovigilance organization through scientific leadership and education.

4.1.1 Scientific Leadership Update

ISoP Academic Coordinator Maribel Salas presented the three-year ISoP Scientific Strategic Plan for 2025–2028 that both Maribel Salas and Strategy Coordinator Tarek Hammad prepared and it is structured around four key pillars:

1. education and capacity building;
2. research, innovative methods and technology;
3. collaboration with institutions and organisations; and
4. communication.

The strategy adopts a multi-stakeholder approach, with SIGs, Chapters, the Scientific Board and individual volunteers engaged in supporting implementation and ensuring alignment across the Society.

The results of the 2026 strategic survey conducted to identify members' needs, gaps and priorities were also presented. The findings highlighted opportunities to improve accessibility and scheduling

of activities, strengthen practical AI capabilities, establish clearer pathways from volunteering to active roles, and maintain a strong focus on training, collaboration, communication and regional access.

ISoP continued to strengthen its scientific leadership in AI by incorporating high-priority pharmacovigilance topics into its AI seminars in North America and Europe.

The webinars were restructured with clearer type of webinars and responsible parties. A range of academic and scientific activities delivered or supported during 2026 was highlighted, including the first ISoP European AI Seminar in Basel, the Mid-Year Symposium in Hatfield, the Global Meeting in Costa Rica and preparations for the 10th ISoP Intelligent Automation Seminar in Boston. Additional activities included the PV Journal Club, new-member welcome meetings, the ISoP Global Survey and a broad programme of SIG and Chapter webinars covering topics such as medication errors, AI in pharmacovigilance, risk communication, vaccine surveillance and risk minimisation methods.

An update was provided on ISoP Patient Safety Day 2026, held on 17–18 September and chaired by Maribel Salas. The programme attracted **1,020 registered participants** and comprised six virtual sessions and one in-person session, in India and a broadcasted session in China. The virtual sessions were delivered over approximately 14 hours, involving nine regional representatives, eight moderators and 22 speakers. The programme covered Africa, Europe, the Middle East, Western Pacific, North America and Latin America.

Of the 1,020 registered participants, 239 attended virtually, while 781 did not attend virtually. In addition, 350+ participants attended in person in India, and the broadcast in China received over 1,000 cumulative views.

The Patient Safety Day initiative had been reorganised with a more global focused with an Executive Committee assignment, involvement from the ISoP Student Community, SIGs, Chapters representing the different regions and the Communications team. Each Chapter designed a regional representative who had the task of identifying topics, moderators and speakers relevant to their respective regions. SIGs were invited to present specific topics; the student community named a representative that collaborate with the logistics of the event, and organizers from previous years were also invited to participate with the acceptance of one of them. Supporting infrastructure and reusable templates were also developed for future Patient Safety Day activities and located at the ISoP SharePoint, with plans for the organisation of the initiative to rotate across regions.

The contributions of the regional representatives, Chapters, speakers, moderators, Executive Committee and wider team were acknowledged.

4.1.2 SIG Update

ISoP SIGs Coordinator Katarina Ilic presented an update on work undertaken to strengthen the sustainability, governance and administration of ISoP's Special Interest Groups (SIGs), with particular attention to leadership succession, reporting and membership engagement.

Date of creation	Special Interest Group (SIG)	SIG Lead	Number of Members
2011	Women's medicines	Mira Harrison-Woolrych (New Zealand)	61
2014	Risk communication	Priya Bahri (Netherlands)	103
2015	Risk Minimization Methods	Jean-Christophe Delumeau (Canada)	175
2017	Herbal and Traditional medicines	Joanne Barnes (New Zealand)	20
2017	Pharmacovigilance Professional Qualification Framework	Jan Petracek (Czech Republic)	56
2017	Medication Errors	Rabih Dabliz (United Arab Emirates)	262
2019	Vaccines	Rebecca Chandler (Sweden)	84
2020	Pharmacogenomics	Qun-Ying Yue (Sweden)	70
2021	Medical Devices	Ladi Owolabi (United States of America)	24
2021	Patient Engagement	Mayada Alkhakany (Iraq)	Report not submitted
2022	EcoPharmacovigilance	Jayesh Pandit (Kenya)	70
2022	Drug Safety in Older Patients	Giovanni Furlan (Italy)	50
2023	Real World Evidence and Big Data	Gianluca Trifirò (Italy)	251
2024	Pharmacovigilance in the community	Rabia Hussain (Malaysia)	34
2024	Artificial Intelligence in Pharmacovigilance	Mohammed Fouda (Saudi Arabia)	212
2025	Advanced Therapy Medicinal Products & and Radiopharmaceuticals	Jim Carlson (United Kingdom)	37

Several SIG leadership transitions were highlighted:

Following the departure of Souad Skalli and Jia-bo Wang, Jo Barnes was appointed Chair and Florence van Hunsel Co-Chair, supporting continuity and shared leadership within the Herbal & Traditional Medicines SIG.

Within the Medication Errors SIG, following completion of the leadership terms of Brian Edwards and Angela Caro, a new rotating leadership model was introduced: Rabih Dabliz (2026–2027), Sophia Trantza (2027–2028), and Lubna Merchant (2028–2029). The model is intended to support shared responsibility, continuity and succession planning.

Leadership renewal for the Drug Safety in Older Patients SIG was reported as ongoing.

Progress was also reported in strengthening SIG reporting and governance. A standardised reporting template had been introduced to improve consistency across all SIGs, supported by targeted follow-up.

A review of active membership was also undertaken for selected SIGs, including Pharmacogenomics, Risk Communication and Drug Safety in Older Patients. This work is intended to improve the accuracy of SIG membership records and support stronger member engagement.

4.2 Goal 2 – Enhance the membership journey by improving benefits, onboarding, and operational support using digital tools.

4.2.1 Member-Centric Plan

ISoP Membership Coordinator Hadir Rostom presented an update on the Member-Centric Plan, which forms part of the ISoP Strategic Plan 2025–2028. The approach aims to strengthen the overall membership journey, improve member engagement and retention, and ensure that members recognise clear value from their involvement with ISoP.

The objective is for both new and existing members to feel recognised, valued and actively engaged in the Society.

A new ISoP Members Spotlight Programme was introduced to recognise both experienced pharmacovigilance professionals and students/early-career members. The programme is based on three principles: Recognise, Amplify and Connect. It aims to celebrate member achievements, increase professional visibility across the global pharmacovigilance community and encourage greater participation within the Society. Benefits include permanent and shareable professional profiles, greater global visibility, recognition of achievements and opportunities for longstanding members to be acknowledged for their contributions to ISoP.

The Spotlight Programme will be run by members for members with Valeria Facciolo as Manager.
As part of this initiative, **ISoP Voices**, a new LinkedIn newsletter and flagship channel for the Members Spotlight Programme, was launched. The newsletter will feature members and their professional journeys, achievements and contributions to pharmacovigilance, providing a platform to share member stories with the wider international community. The successful launch edition featured Dr Shanthi Pal (WHO).


An update was also provided on the ISoP Customer Relationship Management (CRM) Project, which aims to replace the existing membership management system with one central platform connecting members, Chapters, SIGs, Communities, events and communications. A phased implementation during 2027 is planned. The first phase, targeted for Q1, will focus on membership management, including data migration, renewals and payments, Chapter/SIG access, communications and reporting, together with event-management functionality. The second phase, targeted for Q2, will incorporate full Global Meeting event registration into the platform.

The overall programme supports ISoP's move towards a more connected, efficient and member-centred organisation, with improved digital infrastructure, stronger member recognition and engagement, and more streamlined administrative processes.

4.2.2 Membership and Chapter Report

ISoP Secretary General Felipe Villalobos presented the Membership and Chapter Report, providing an overview of membership trends, the geographical distribution of members, membership generated through ISoP events, Chapter activities and recent Chapter elections.

ISoP reported **1,397** active members in 2026. Membership had grown substantially over recent years. The 2026 figure represented a slight reduction from the previous year.



ISoP events continued to provide an important route for attracting new members. Membership generated through recent Global Meetings, Mid-Year Symposia, AI Seminars and Chapter events was highlighted.

Report from Chapters

ISoP Chapter	Chapter Leader	Active Members
Europe	Linda Härmark	521
North America (NASoP)	Marina Malikova (Acting)	239
Africa	Comfort Ogar	185
Middle East & North Africa (MENA)	Abeer Zeitoun	167
Latin America (LATAM)	Cinthya Galicia	136
Western Pacific	Navinisha Lee	72
South Asia	Moin Don	35
Indonesia	Jarir At Thobari	25
China	Li Zhang	17
Total		**1,397**

Key 2026 Chapter highlights included the first European AI Seminar, in collaboration with the Europe Chapter, held in Basel on 16–17 February with 125 participants; the Africa Chapter Annual Meeting in Windhoek, Namibia, from 18–20 May, which attracted more than 200 delegates; and the ISoP Mid-Year Symposium in Hatfield on 9–10 June, attended by 104 participants.

An update was also provided on Chapter elections and new leadership. The first Executive Committee elections for the new MENA Chapter were completed in August 2026 and the Latin America Chapter (LATAM) also completed its Executive Committee elections in February 2026.

Overall, the report demonstrated the geographical diversity of the ISoP membership, together with the important contribution of Chapters and ISoP scientific events to member recruitment, regional engagement and leadership development.

4.2.3 Communities and Mentorship Report

Felipe Villalobos presented the Communities and Mentorship Report on behalf of Brian Edwards, ISoP Communities and Mentorship Coordinator, providing updates on the ISoP Industry Community, Fellows engagement and the development of the ISoP Mentorship Programme.

The ISoP Industry Community had grown to 82 members and was holding monthly meetings. Activities were being coordinated by Joanne Holley and Jamal Baig, with restructuring planned and additional project-management support required.

An update was also provided on the ISoP Fellows Community and Engagement Survey. The findings demonstrated a highly experienced and engaged Fellows community. The survey also demonstrated interest in supporting mentorship activities, with eight Fellows expressing an interest in serving as mentors and others indicating that they may be interested.

Progress on the ISoP Mentorship Programme was also reported. The programme guidelines had been approved and a training guide made available. The initial mentor group comprised Salvatore Crisafulli, Kenneth Hartigan-Go and Brian Edwards, together with one additional volunteer. A pilot was planned to commence in October 2026 with two mentor–mentee pairs. It was also noted that NASoP had established its own mentorship scheme, and NASoP members were encouraged to apply through their Chapter's mentorship programme rather than the ISoP Mentorship Programme. This was a recommendation rather than an exclusion, and NASoP members remained eligible to participate in the ISoP programme.

The overall objective of the mentorship initiative is to translate the knowledge and experience of ISoP Fellows and senior members into practical support for the next generation of pharmacovigilance professionals, while strengthening connections and knowledge transfer across the Society.

4.2.4 Student Coordination Report

ISoP Communication & Students Coordinator, Salvatore Crisafulli presented an update on the ISoP Student Group, which comprised 81 student members across 42 countries. He highlighted the Group's leadership structure and explained that the focus during 2026 had been on integrating students into wider ISoP activities and initiatives, rather than organising separate student activities.

Key activities during the year included the Students' Travel Grant and Award, the Student Group Meet & Greet at the ISoP Global Meeting, and increased interaction through ISoP social media channels. Student representation had also been incorporated into the Patient Safety Day (PSD) Planning Committee, further integrating students into Society-wide activities.

The Student Community had published a position paper in Drug Safety addressing the role of the ISoP Student Community and the future of pharmacovigilance. *https://link.springer.com/article/10.1007/s40264-026-01651-z*

Further academic activity included work on a perspective article summarising the state of the art in Artificial Intelligence in Pharmacovigilance, arising from the 2026 ISoP AI Seminar in Basel.

The Student Group was also participating in the development of the ISoP Mentorship Programme, in collaboration with the Communities and Mentorship Coordinator, with the objective of supporting the academic and professional development of ISoP student members.

4.3 Goal 3 – Enhance the membership journey by improving benefits, onboarding, and operational support using digital tools.

4.3.1 Communications Report

Salvatore Crisafulli presented the Communications Report, highlighting the continued growth of ISoP's digital presence and the implementation of the revised communications structure. For the reporting period 31 October 2025 to 4 August 2026, ISoP recorded a combined total of 26,090 followers across its social media accounts, representing an increase of 5,269 followers (25.3%). The Society achieved approximately 672,000 impressions and 283,000 in reported reach, alongside more than 20 event-related posts.

The revised communications structure distinguishes between ISoP Online, which focuses on membership engagement and the Society's scientific activities, and ISoP Events, a dedicated LinkedIn channel promoting ISoP-organised events. As of August 2026, ISoP Online had 23,269 followers, while ISoP Events had grown to 2,821 followers, representing a 106% increase since October 2025. LinkedIn remained the Society's strongest platform, with particularly encouraging growth across both channels.

The results demonstrated sustained growth in ISoP's digital audience, increased visibility of its scientific and educational activities, and the positive impact of the revised communications approach.

4.3.2 Global Outreach and Strategic Partnerships

ISoP President Omar Aimer and ISoP Vice-President Francesco Salvo presented an update on ISoP's global outreach and strategic partnerships, highlighting the continued development of the Society's international network as a strategic asset.

Five new principal partnerships and collaborations were highlighted for 2026:

Partner / Network	Area of Collaboration
WHO & CIP Network	Collaboration to strengthen pharmacovigilance capacity and international regulatory convergence.
ICH	Ongoing collaboration supporting global harmonisation and patient safety through pharmacovigilance. Memorandum of Understanding signed 17 July 2026.
VAC4EU	Collaboration to enhance vaccine safety monitoring and capacity building across Europe and beyond.
SEARN	Collaboration to strengthen pharmacovigilance across the South and East Asia region.

Partner / Network	Area of Collaboration
FIP	Joint efforts to advance the safe and effective use of medicines through education, research and professional development.

ISoP Africa Rotation Placement Pilot

An update was provided on the ISoP Africa Rotation Placement Pilot, led by Francesco Salvo and Mouna Abane (France). This new initiative aims to provide selected African pharmacovigilance professionals with a 3–6-month practical placement outside Africa, enabling participants to gain hands-on experience in essential pharmacovigilance activities under appropriate supervision.

The pilot follows a structured pathway covering host-site identification, candidate assessment, matching, contracting and placement. The intention is that participants return to their country or region of origin and transfer the knowledge and skills gained through peer training and capacity-building activities.

ISoP Training Initiative in Africa

The ISoP Training Initiative in Africa was also presented by Omar Aimer. This new initiative is intended to strengthen practical pharmacovigilance competencies within African National Regulatory Authorities (NRAs), particularly in countries progressing towards WHO Global Benchmarking Tool Maturity Level 3 (ML3).

Two regional, in-person training programmes were planned for the first and second quarters of 2027 (Q1 and Q2), with a Francophone cohort in Dakar, Senegal, and an Anglophone cohort in Addis Ababa, Ethiopia. The exact dates for both programmes were yet to be confirmed. Each programme was designed for approximately 15–20 participants, delivered through four half-day modules over two days.

Country and participant selection would take account of readiness to progress towards ML3, identified pharmacovigilance gaps, institutional commitment, regional and linguistic balance, and participants' ability to apply and disseminate the learning within their organisations.

The expected outcomes included strengthened national pharmacovigilance competencies, practical implementation tools, stronger and more functional pharmacovigilance systems, enhanced regional collaboration and knowledge-sharing, and ultimately a contribution to safer medicines and improved health outcomes across Africa.

Omar also highlighted the ambition to expand the initiative to additional African countries, potentially including future training programmes delivered in Portuguese and Spanish.

4.4 Goal 4 – Strengthen ISoP's reputation as the global pharmacovigilance organization while enhancing engaging communication with members

4.4.1 Treasurer's Financial Report

ISoP Treasurer, Comfort Ogar presented the Financial Report, providing an overview of ISoP's projected financial position as at 30 September 2026 (interim accounts), together with comparative figures for 2025, income and expenditure performance, and the revised membership fee structure for 2027.

Financial Position

The Society reported a strengthened financial position compared with the previous year:

Projected 2026 Balance sheet compared to 2025

EUR	Sept 2026	Sept 2025	
Current Asset	439'901	259'782	Cash in bank and in hand as at Aug 31, 2026
Liabilities	(62'681)	(23'720)	Projected liabilities as at Sept 30, 2026
Net Assets	377'220	236'062	Projected at Sept 30, 2026

The projected September 2026 net assets were based on cash in bank and in hand as at **31 August 2026**, and liabilities projected to be paid on or before 30 September 2026 as provided by the ISoP Accountant in Geneva.

Comparing the 2026 end of fiscal year net assess and income against the 2025 figures for the same period provides a quick overview of the financial health of the society in the last one year.

Income 2026 vs 2025

Income increased by about 29% compared to 2025

Income (EUR)	2026	2025	Comments
Membership fees	74'409	70'688	A slight deep in discounted membership subscription leading to net deep in total membership fees earned in the last year.
Discounted membership fees	48'655	54'880	
Total membership fees	123'064	125'568	
Training income	82'965	33'884	145% Increase in income from successful ISoP trainings and meetings (Global and Regional)
External funding	108'910		First time of attracting donor funding to execute projects
Other income	106	297	
Total inflow	**315'045**	**159'749**	**Inflow increased by EUR.155'296 (97%). Income accruable to ISoP increased by EUR. 46,386 (29%)**
Total income to ISoP	**206'135**	**159'749**	

66

Income attributable to ISoP increased by approximately **29% compared with 2025**, from €159,749 to €206,135.

The increase was principally supported by strong training and meeting income, which increased substantially compared with 2025. The Society also secured external donor funding for the first time to support the delivery of projects.

Total inflow increased by **€155,296 (97%)**, while income attributable to ISoP increased by **€46,386 (29%)**.

Expenditure and Financial Result

Overall expenditure remained broadly stable and decreased by approximately **0.5%**, from €159,700 in 2025 to €158,887 in 2026.

The increase in payroll reflected increased working hours and salary costs, while expenditure on the *Drug Safety* subscription decreased as a result of reduced utilisation by members.

Profit before tax was reported at **€156,158**, including external funding. Following projected taxes of €15,000, the net result including funding was **€141,158**. Excluding external funding, the presentation reported a **net profit of €32,248**.

Membership Fees

The proposed 2027 membership structure for all ISoP members (past, current, and new) was presented as part of an initiative to simplify and align membership fees:

Membership Category	Annual Fee	Eligibility
Standard Membership	**€249**	Individual members from HICs affiliated with a commercial organisation
Reduced Membership	**€99**	HIC members affiliated with a not-for-profit organisation; LMIC members affiliated with a commercial organisation; students from HICs
Special Reduced Membership	**€49**	LMIC members affiliated with a not-for-profit organisation; students from LMICs

The General Assembly approved the membership fees for all ISoP members, effective January 2027. It also approved the interim accounts covering 1 October 2025 to 31 August 2026.

Financial Outlook

Comfort Ogar reported that the Society had achieved its financial break-even objective in 2026 and generated a surplus that would support continued investment in organisational development, including more efficient operations and improvements to member services.

The financial strategy for the coming period would focus on sustaining membership growth, retaining existing members, attracting new members, investing in organisational infrastructure and strategic partnerships, and maintaining prudent financial management.

It was noted that ISoP intended to continue investing in initiatives that support pharmacovigilance and patient safety while maintaining a member-centred and financially sustainable organisation.

5. Fellowship and Honorary Awards 2026

Presented by Omar Aimer, Francesco Salvo, and Felipe Villalobos.

The General Assembly recognised the recipients of the 2026 ISoP Fellowship Awards and the 2026 ISoP Honorary Member Award, acknowledging individuals who have made significant contributions to ISoP and the wider international pharmacovigilance community.

ISoP Fellowship Awards 2026

ISoP Fellows have made substantial contributions to the discipline of pharmacovigilance through their work (including publications or similar outputs) and have also shown services to the Society, for example, by involvement in ISoP meetings, and/or by leadership of ISoP Chapters and Special Interest Groups (SIG's).

Seven members were presented with the ISoP Fellowship Award 2026. The recipients are listed below in alphabetical order by surname:

- Mohamed A. Elhawary
- Maxine Gossel-Williams
- Tarek Hammad
- Marina Malikova
- Lubna Merchant
- Mónica Tarapués
- Liliana Vargas Neri

ISoP Honorary Member Award 2026

The 2026 ISoP Honorary Member Award was presented to Dr Shanthi Narayan Pal – World Health Organization (WHO) in recognition of her exceptional contribution to the international pharmacovigilance and medicines safety community.

Shanthi Pal was recognised as an internationally respected leader in pharmacovigilance and medicines safety, with significant contributions to strengthening global pharmacovigilance systems and protecting patients worldwide.

Her contributions highlighted during the presentation included work in global medicines safety, including pharmacovigilance systems, adverse drug reaction reporting and post-marketing safety surveillance through her work with WHO Headquarters in Geneva. Her contribution to scientific innovation included research relating to Smart Safety Surveillance (3S), cohort event monitoring and digital and mobile technologies for medicines safety.

6. Looking Ahead (ISoP events)

ISop President, Omar Aimer presented an overview of the Society's forthcoming international events, highlighting the programme of activities planned from late 2026 through 2028.

The upcoming ISoP events were presented as follows:

Year	Event	Dates	Location
2026	10th ISoP Seminar – Intelligent Automation in Pharmacovigilance	3–4 December 2026	Boston–Cambridge, USA
2027	ISoP Mid-Year Symposium 2027	2–3 June 2027	Abu Dhabi, UAE
2027	26th ISoP Global Meeting	14–17 September 2027	Bordeaux, France
2028	27th ISoP Global Meeting	18–21 September 2028	Johannesburg, South Africa

Looking further ahead, the 27th ISoP Global Meeting was confirmed for Johannesburg, South Africa, from 18–21 September 2028.

7. Q&A

Following the presentations, the floor was opened for questions and comments. Members were reminded that any questions not addressed during the session could be submitted to the ISoP Secretariat for follow-up. Katarina Ilic also reminded members to keep their email addresses and affiliations up to date and asked SIG leaders to ensure that their membership lists remained accurate and that relevant updates were communicated through the appropriate ISoP channels.

Priya Bahri from the Netherlands welcomed the progress made by the Society and commented positively on ISoP's financial position. She asked for clarification regarding the source of the new donor funding and strongly supported investment in a new membership platform to assist the Secretariat, particularly Sophie Spence and Antoinette Ivins, with the increasing administrative workload. She also encouraged greater collaboration across SIGs through common strategic themes and highlighted the importance of extending pharmacovigilance awareness and education to prescribers. In response, **Omar Aimer** confirmed that the donor funding was provided by the Gates Foundation in support of regulatory pharmacovigilance training in Africa and noted the ongoing collaboration with the ISoP Africa Chapter.

Luis Velez from Switzerland reiterated a request first raised at the previous General Assembly in Cairo concerning the length of the ISoP President's term. **Omar Aimer** responded that the matter had previously been discussed and explained that the three-year term was intended to provide sufficient time for the President and Executive Committee to implement the Society's strategic plan and achieve measurable results. He added that ISoP remained committed to reviewing and strengthening its governance framework and maintaining dialogue on governance matters.

8. Remarks from ISoP President

In closing, Omar Aimer thanked the EC and AB members for their continued commitment and contributions to the Society. Special appreciation was also extended to Sophie Spence and Antoinette Ivins for their work supporting the ISoP administration and Secretariat, and to Gabriela Durán for her communications and design support, and to all those involved in ISoP for their support and contributions.

Special thanks were given to Angela Caro, Chair of the Scientific Committee, and Betty Duarte, Chair of the Local Organising Committee, for their leadership and contribution to the successful organisation of the 25th ISoP Global Meeting. Appreciation was also extended to the other members of the Scientific Committee: Betty Duarte, Gloria Giraldo, Ulrich Hagemann, Comfort Ogar, Marina Malikova, Elki Sollenbring and Ryan Walker; and the Local Organising

Committee: Xiomara Vega, Yajaira Quesada, Diego Salas, Mario Torrero, Liliana Vargas, Patricia Zuluaga and Victoria Hall**.**

Gratitude was expressed to the ISoP Latin America Chapter, the Local Organising Committee and Scientific Committee for their collective contribution to the organisation and delivery of the 2026 Global Meeting in San José, Costa Rica.

The General Assembly concluded with sincere appreciation to all members and contributors for their dedication to advancing pharmacovigilance and the safer use of medicines worldwide. Participants were warmly invited to attend the 26th ISoP Global Meeting, to be held in Bordeaux, France, from 14–17 September 2027.

The meeting closed at 13:15 (UTC−6; 19:15 UTC)

Draft prepared: 15 October 2026

Omar Aimer ……

Omar Aimer

ISoP President

…….

Felipe Villalobos

ISoP Secretary General